YERVOY

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug YERVOY contains one active pharmaceutical ingredient (API):

1 Ipilimumab UNII 6T8C155666 - IPILIMUMAB

Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of reactive T-effector cells which mobilize to mount a direct T-cell immune attack against tumour cells. CTLA-4 blockade can also reduce T-regulatory cell function, which may contribute to an anti-tumour immune response. Read about Ipilimumab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
YERVOY Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX04	Ipilimumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11628B, 11644W, 12304N, 12308T, 12322M, 12324P, 12583G, 12601F, 2638W, 2641B
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 505112120019302, 505112120019402
Country: CA	Health Products and Food Branch	Identifier(s): 02379384
Country: EE	Ravimiamet	Identifier(s): 1536926, 1536937
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 11698001, 11698001IP, 11698002
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 065544, 482727
Country: FR	Base de données publique des médicaments	Identifier(s): 66532840
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 193816, 193828, 369087, 377767
Country: HK	Department of Health Drug Office	Identifier(s): 63494, 63495
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 6931, 6932
Country: IT	Agenzia del Farmaco	Identifier(s): 041275013, 041275025
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291430A1026, 4291430A2022
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1061650, 1061651
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 101052, 101060
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 15165, 15352
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100249251
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W65565001, W65565002
Country: SG	Health Sciences Authority	Identifier(s): 14598P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699726764109, 8699726764505
Country: US	FDA, National Drug Code	Identifier(s): 0003-2327, 0003-2328
Country: ZA	Health Products Regulatory Authority	Identifier(s): 47/30.1/0522